Interleukin 6 (IL-6) and soluble IL-2 receptor levels in patients with rheumatoid arthritis treated with low dose oral methotrexate

A Crilly, I B McInness, A G McDonald, J Watson, H A Capell, R Madhok

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: To investigate the effect of oral methotrexate (MTX) on circulating levels of interleukin 6 (IL-6) and soluble IL-2 receptor (sIL-2R) in patients with rheumatoid arthritis (RA).

METHODS: We measured serum concentrations of IL-6 (n = 20) and sIL-2R (n = 16) before MTX therapy and again after 12 weeks.

RESULTS: MTX significantly reduced IL-6 and sIL-2R after 12 weeks of therapy, and although the levels remained low at 24 weeks of therapy, the reduction was not significant. Reduction in cytokine levels was paralleled by an improvement in clinical indices. Placebo treatment did not significantly alter IL-6 or sIL-2R.

CONCLUSION: MTX appears capable of cytokine modulation, although the mechanism is not clear.

Original languageEnglish
Pages (from-to)224-6
Number of pages3
JournalThe Journal of Rheumatology
Volume22
Issue number2
Publication statusPublished - Feb 1995

Fingerprint

Interleukin-2 Receptors
Methotrexate
Interleukin-6
Rheumatoid Arthritis
Cytokines
Therapeutics
Placebos
Serum

Keywords

  • Administration, Oral
  • Arthritis, Rheumatoid
  • Dose-Response Relationship, Drug
  • Humans
  • Interleukin-6
  • Methotrexate
  • Middle Aged
  • Receptors, Interleukin-2
  • Solubility

Cite this

Crilly, A ; McInness, I B ; McDonald, A G ; Watson, J ; Capell, H A ; Madhok, R. / Interleukin 6 (IL-6) and soluble IL-2 receptor levels in patients with rheumatoid arthritis treated with low dose oral methotrexate. In: The Journal of Rheumatology. 1995 ; Vol. 22, No. 2. pp. 224-6.
@article{00eef440609f45ffabab15d4e116d006,
title = "Interleukin 6 (IL-6) and soluble IL-2 receptor levels in patients with rheumatoid arthritis treated with low dose oral methotrexate",
abstract = "OBJECTIVE: To investigate the effect of oral methotrexate (MTX) on circulating levels of interleukin 6 (IL-6) and soluble IL-2 receptor (sIL-2R) in patients with rheumatoid arthritis (RA).METHODS: We measured serum concentrations of IL-6 (n = 20) and sIL-2R (n = 16) before MTX therapy and again after 12 weeks.RESULTS: MTX significantly reduced IL-6 and sIL-2R after 12 weeks of therapy, and although the levels remained low at 24 weeks of therapy, the reduction was not significant. Reduction in cytokine levels was paralleled by an improvement in clinical indices. Placebo treatment did not significantly alter IL-6 or sIL-2R.CONCLUSION: MTX appears capable of cytokine modulation, although the mechanism is not clear.",
keywords = "Administration, Oral, Arthritis, Rheumatoid, Dose-Response Relationship, Drug, Humans, Interleukin-6, Methotrexate, Middle Aged, Receptors, Interleukin-2, Solubility",
author = "A Crilly and McInness, {I B} and McDonald, {A G} and J Watson and Capell, {H A} and R Madhok",
year = "1995",
month = "2",
language = "English",
volume = "22",
pages = "224--6",
journal = "The Journal of Rheumatology",
issn = "0315-162X",
publisher = "The Journal of Rheumatology Publishing Company Limited",
number = "2",

}

Interleukin 6 (IL-6) and soluble IL-2 receptor levels in patients with rheumatoid arthritis treated with low dose oral methotrexate. / Crilly, A; McInness, I B; McDonald, A G; Watson, J; Capell, H A; Madhok, R.

In: The Journal of Rheumatology, Vol. 22, No. 2, 02.1995, p. 224-6.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Interleukin 6 (IL-6) and soluble IL-2 receptor levels in patients with rheumatoid arthritis treated with low dose oral methotrexate

AU - Crilly, A

AU - McInness, I B

AU - McDonald, A G

AU - Watson, J

AU - Capell, H A

AU - Madhok, R

PY - 1995/2

Y1 - 1995/2

N2 - OBJECTIVE: To investigate the effect of oral methotrexate (MTX) on circulating levels of interleukin 6 (IL-6) and soluble IL-2 receptor (sIL-2R) in patients with rheumatoid arthritis (RA).METHODS: We measured serum concentrations of IL-6 (n = 20) and sIL-2R (n = 16) before MTX therapy and again after 12 weeks.RESULTS: MTX significantly reduced IL-6 and sIL-2R after 12 weeks of therapy, and although the levels remained low at 24 weeks of therapy, the reduction was not significant. Reduction in cytokine levels was paralleled by an improvement in clinical indices. Placebo treatment did not significantly alter IL-6 or sIL-2R.CONCLUSION: MTX appears capable of cytokine modulation, although the mechanism is not clear.

AB - OBJECTIVE: To investigate the effect of oral methotrexate (MTX) on circulating levels of interleukin 6 (IL-6) and soluble IL-2 receptor (sIL-2R) in patients with rheumatoid arthritis (RA).METHODS: We measured serum concentrations of IL-6 (n = 20) and sIL-2R (n = 16) before MTX therapy and again after 12 weeks.RESULTS: MTX significantly reduced IL-6 and sIL-2R after 12 weeks of therapy, and although the levels remained low at 24 weeks of therapy, the reduction was not significant. Reduction in cytokine levels was paralleled by an improvement in clinical indices. Placebo treatment did not significantly alter IL-6 or sIL-2R.CONCLUSION: MTX appears capable of cytokine modulation, although the mechanism is not clear.

KW - Administration, Oral

KW - Arthritis, Rheumatoid

KW - Dose-Response Relationship, Drug

KW - Humans

KW - Interleukin-6

KW - Methotrexate

KW - Middle Aged

KW - Receptors, Interleukin-2

KW - Solubility

M3 - Article

VL - 22

SP - 224

EP - 226

JO - The Journal of Rheumatology

JF - The Journal of Rheumatology

SN - 0315-162X

IS - 2

ER -